| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
SU 4313 is a broad-spectrum protein tyrosine kinase (PTK) modulator that inhibits multiple receptor tyrosine kinases. It inhibits PDGFR (14.5 μM), FLK-1/VEGFR2 (18.8 μM), EGFR (11 μM), HER2 kinase (16.9 μM), and IGF-1R (8.0 μM). By inhibiting these kinases, SU 4313 modulates signaling pathways involved in cell proliferation, survival, and angiogenesis. The compound is a 3-benzylidene-indolin-2-one that functions as a broad-spectrum PTK modulator.
|
|---|---|
| ln Vitro |
In vitro, SU 4313 is a potent protein tyrosine kinase (PTK) modulator. It inhibits PDGFR with an IC50 of 14.5 μM, FLK-1 with 18.8 μM, EGFR with 11 μM, HER2 kinase with 16.9 μM, and IGF-1R with 8.0 μM. Its in vitro activity is characterized by broad-spectrum inhibition of receptor tyrosine kinases. SU 4313 is used as a research tool to study tyrosine kinase signaling pathways.
|
| ln Vivo |
In vivo, SU 4313 has been studied for its potential anti-tumor effects in preclinical models. As a broad-spectrum PTK modulator, it may inhibit multiple signaling pathways involved in tumor growth and angiogenesis. However, detailed in vivo efficacy data for specific disease models are limited in the available literature. SU 4313 is primarily used as a research tool for studying tyrosine kinase biology.
|
| Enzyme Assay |
In vitro enzyme assays for SU 4313 typically involve measuring the inhibition of various receptor tyrosine kinases, including PDGFR, FLK-1, EGFR, HER2 kinase, and IGF-1R. The compound shows IC50s of 14.5, 18.8, 11, 16.9, and 8.0 μM, respectively. These assays confirm the compound's mechanism of action as a broad-spectrum PTK modulator.
|
| Cell Assay |
In vitro cellular assays for SU 4313 typically involve treating cancer cell lines with the compound and measuring cell proliferation, apoptosis, or signaling pathway modulation. The compound inhibits multiple receptor tyrosine kinases, leading to the modulation of downstream signaling pathways. These cell-based studies demonstrate the compound's broad-spectrum inhibitory activity.
|
| Animal Protocol |
In vivo animal models for SU 4313 may include xenograft tumor models to evaluate its anti-tumor effects. The compound is administered by appropriate routes, and tumor growth inhibition is measured. However, detailed animal protocol information for SU 4313 is limited in the available literature. The compound is primarily used as a research tool for studying tyrosine kinase biology.
|
| ADME/Pharmacokinetics |
SU 4313 has a molecular formula of C18H17NO and a molecular weight of 263.33 g/mol. The compound is typically stored under appropriate conditions to maintain stability. Its physicochemical properties support its use in both in vitro and in vivo studies. SU 4313's solubility and formulation for administration should be optimized based on specific experimental requirements. The compound is a potent protein tyrosine kinase modulator.
|
| Toxicity/Toxicokinetics |
SU 4313 is a broad-spectrum PTK modulator with a well-characterized mechanism of action. As with any kinase inhibitor, potential toxicity may include off-target effects on other kinases and disruption of normal cellular signaling. The compound's safety profile should be evaluated in preclinical toxicology studies. SU 4313 is for research use only and is not approved for human therapeutic use. It represents a valuable tool for studying tyrosine kinase signaling pathways.
|
| References |
: Weigl K, Jansen L, Chang-Claude J, Knebel P, Hoffmeister M, Brenner H. Family history and the risk of colorectal cancer: The importance of patients' history of colonoscopy. Int J Cancer. 2016 Nov 15;139(10):2213-20. doi: 10.1002/ijc.30284. PubMed PMID: 27459311.
|
| Additional Infomation |
SU 4313 (CAS# 186611-55-2) is a potent protein tyrosine kinase (PTK) modulator with IC50s of 14.5 μM for PDGFR, 18.8 μM for FLK-1 (VEGFR2), 11 μM for EGFR, 16.9 μM for HER2 kinase, and 8.0 μM for IGF-1R. It is a small-molecule modulator of protein tyrosine kinases (PTKs). The compound is for research use only and is not approved for human therapeutic use.
|
| Molecular Formula |
C18H17NO
|
|---|---|
| Molecular Weight |
263.33368
|
| Exact Mass |
263.131
|
| CAS # |
186611-55-2
|
| Related CAS # |
186611-55-2;
|
| PubChem CID |
1538822
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.44
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
390
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C1C=CC(/C=C2/C3C(=CC=CC=3)NC/2=O)=CC=1)C
|
| InChi Key |
IRQQWCZKCUQNSO-LFIBNONCSA-N
|
| InChi Code |
InChI=1S/C18H17NO/c1-12(2)14-9-7-13(8-10-14)11-16-15-5-3-4-6-17(15)19-18(16)20/h3-12H,1-2H3,(H,19,20)/b16-11+
|
| Chemical Name |
(3E)-3-[(4-propan-2-ylphenyl)methylidene]-1H-indol-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7975 mL | 18.9876 mL | 37.9752 mL | |
| 5 mM | 0.7595 mL | 3.7975 mL | 7.5950 mL | |
| 10 mM | 0.3798 mL | 1.8988 mL | 3.7975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA